B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients.

ABSTRACT: Patients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses post 3^rd and 4^th dose of the BNT162b2 vaccine differed between PoD and controls. Non-infected PoD and controls vaccinated with BNT162b2 were recruited in Ziv Medical Center, Israel, between 2021 and 2022. Specimens were collected 1-2 months pre 3^rd dose; 1-3 months post 3^rd dose; 4-5 months post 3^rd dose and 3-5 months post the 4^th dose. Anti-SARS-CoV-2 spike (spike) specific antibodies, spike specific memory B cells, and spike specific CD15

SUBMITTER: Bathish Y 

PROVIDER: S-EPMC10793709 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature